EG24223A - Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof - Google Patents

Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof

Info

Publication number: EG24223A
Authority: EG; Egypt
Prior art keywords: piperidin; benzo; methoxyphenyl; phenoxy; ethoxy
Prior art date: 2000-05-08

Application number

EG20010461A

Other languages

English (en)

Inventor

Bashore N Fadia

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-08

Filing date

2001-05-05

Publication date

2008-11-10

2001-05-05 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2008-11-10 Application granted granted Critical

2008-11-10 Publication of EG24223A publication Critical patent/EG24223A/xx

Links

150000003839 salts Chemical class 0.000 title abstract 3
125000005605 benzo group Chemical group 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
238000000354 decomposition reaction Methods 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EG20010461A 2000-05-08 2001-05-05 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof EG24223A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20323500P	2000-05-08	2000-05-08

Publications (1)

Publication Number	Publication Date
EG24223A true EG24223A (en)	2008-11-10

Family

ID=22753086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG20010461A EG24223A (en)	2000-05-08	2001-05-05	Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof

Country Status (30)

Country	Link
EP (1)	EP1357903B1 (fr)
JP (1)	JP2003535827A (fr)
KR (1)	KR100806992B1 (fr)
CN (1)	CN1283250C (fr)
AR (1)	AR028401A1 (fr)
AT (1)	ATE348605T1 (fr)
AU (2)	AU5531001A (fr)
BR (1)	BR0110620A (fr)
CA (2)	CA2691739A1 (fr)
CZ (1)	CZ20023651A3 (fr)
DE (1)	DE60125416T2 (fr)
DZ (1)	DZ3376A1 (fr)
EA (1)	EA004871B1 (fr)
EC (1)	ECSP014066A (fr)
EG (1)	EG24223A (fr)
ES (1)	ES2276784T3 (fr)
HR (1)	HRP20020883A2 (fr)
HU (1)	HUP0302190A3 (fr)
IL (2)	IL152699A0 (fr)
MX (1)	MXPA02010923A (fr)
NO (1)	NO20025219L (fr)
NZ (1)	NZ521393A (fr)
PE (1)	PE20011255A1 (fr)
PL (1)	PL365472A1 (fr)
SK (1)	SK286346B6 (fr)
SV (1)	SV2002000435A (fr)
TW (1)	TWI225787B (fr)
UA (1)	UA77941C2 (fr)
WO (1)	WO2001085147A2 (fr)
ZA (1)	ZA200207651B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6653479B1 (en)	1999-07-29	2003-11-25	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US6610706B1 (en)	1999-07-29	2003-08-26	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US20070066578A1 (en) *	2003-09-22	2007-03-22	Noboru Shimizu	5-Aminosalicylic acid solid preparation improved in discoloration and method of storing the same
WO2016024369A1 (fr) *	2014-08-13	2016-02-18	テバ製薬株式会社	Composition médicinale pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE44597A1 (es) *	1995-02-28	1997-10-13	Lilly Co Eli	Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
ES2208384T3 (es) *	1999-07-29	2004-06-16	Eli Lilly And Company	Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
EP1204656A2 (fr) *	1999-07-29	2002-05-15	Eli Lilly And Company	NOUVELLE FORME CRISTALLINE DE CHLORHYDRATE DE 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO b]THIOPHENE
AU780211B2 (en) *	1999-07-29	2005-03-10	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride

2001
- 2001-04-30 AT AT01928454T patent/ATE348605T1/de not_active IP Right Cessation
- 2001-04-30 CA CA002691739A patent/CA2691739A1/fr not_active Abandoned
- 2001-04-30 UA UA2002118788A patent/UA77941C2/uk unknown
- 2001-04-30 AU AU5531001A patent/AU5531001A/xx active Pending
- 2001-04-30 ES ES01928454T patent/ES2276784T3/es not_active Expired - Lifetime
- 2001-04-30 CZ CZ20023651A patent/CZ20023651A3/cs unknown
- 2001-04-30 KR KR1020027014923A patent/KR100806992B1/ko not_active Expired - Fee Related
- 2001-04-30 IL IL15269901A patent/IL152699A0/xx unknown
- 2001-04-30 PL PL01365472A patent/PL365472A1/xx not_active Application Discontinuation
- 2001-04-30 HU HU0302190A patent/HUP0302190A3/hu unknown
- 2001-04-30 HR HR20020883A patent/HRP20020883A2/hr not_active Application Discontinuation
- 2001-04-30 CA CA002408563A patent/CA2408563A1/fr not_active Abandoned
- 2001-04-30 WO PCT/US2001/011736 patent/WO2001085147A2/fr not_active Ceased
- 2001-04-30 EP EP01928454A patent/EP1357903B1/fr not_active Expired - Lifetime
- 2001-04-30 DZ DZ013376A patent/DZ3376A1/fr active
- 2001-04-30 DE DE60125416T patent/DE60125416T2/de not_active Expired - Fee Related
- 2001-04-30 EA EA200201186A patent/EA004871B1/ru not_active IP Right Cessation
- 2001-04-30 AU AU2001255310A patent/AU2001255310C1/en not_active Ceased
- 2001-04-30 CN CNB018091296A patent/CN1283250C/zh not_active Expired - Fee Related
- 2001-04-30 MX MXPA02010923A patent/MXPA02010923A/es active IP Right Grant
- 2001-04-30 JP JP2001581801A patent/JP2003535827A/ja active Pending
- 2001-04-30 NZ NZ521393A patent/NZ521393A/en unknown
- 2001-04-30 SK SK1565-2002A patent/SK286346B6/sk not_active IP Right Cessation
- 2001-04-30 BR BR0110620-1A patent/BR0110620A/pt not_active Application Discontinuation
- 2001-05-02 TW TW090110500A patent/TWI225787B/zh not_active IP Right Cessation
- 2001-05-02 AR ARP010102074A patent/AR028401A1/es unknown
- 2001-05-04 PE PE2001000402A patent/PE20011255A1/es not_active Application Discontinuation
- 2001-05-05 EG EG20010461A patent/EG24223A/xx active
- 2001-05-07 SV SV2001000435A patent/SV2002000435A/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004066A patent/ECSP014066A/es unknown
2002
- 2002-09-23 ZA ZA200207651A patent/ZA200207651B/en unknown
- 2002-10-31 NO NO20025219A patent/NO20025219L/no not_active Application Discontinuation
- 2002-11-07 IL IL152699A patent/IL152699A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1061349A1 (en)	2004-09-17
HUP0302190A3 (en)	2009-03-30
MXPA02010923A (es)	2003-03-27
JP2003535827A (ja)	2003-12-02
WO2001085147A2 (fr)	2001-11-15
NO20025219D0 (no)	2002-10-31
IL152699A (en)	2009-09-01
CZ20023651A3 (cs)	2003-02-12
CA2408563A1 (fr)	2001-11-15
CN1283250C (zh)	2006-11-08
EP1357903B1 (fr)	2006-12-20
ES2276784T3 (es)	2007-07-01
AU2001255310B8 (en)	2005-03-10
AR028401A1 (es)	2003-05-07
ATE348605T1 (de)	2007-01-15
DE60125416D1 (de)	2007-02-01
KR20030009477A (ko)	2003-01-29
AU2001255310C1 (en)	2006-03-09
PL365472A1 (en)	2005-01-10
ECSP014066A (es)	2002-02-25
AU2001255310B2 (en)	2005-03-03
WO2001085147A3 (fr)	2003-08-28
EP1357903A2 (fr)	2003-11-05
UA77941C2 (en)	2007-02-15
AU5531001A (en)	2001-11-20
EA200201186A1 (ru)	2003-08-28
SK286346B6 (en)	2008-07-07
HRP20020883A2 (en)	2005-02-28
KR100806992B1 (ko)	2008-02-25
NZ521393A (en)	2004-08-27
DZ3376A1 (fr)	2001-11-15
ZA200207651B (en)	2003-12-23
SK15652002A3 (sk)	2003-04-01
PE20011255A1 (es)	2001-12-11
IL152699A0 (en)	2003-06-24
NO20025219L (no)	2002-10-31
SV2002000435A (es)	2002-10-24
DE60125416T2 (de)	2007-09-27
CN1545413A (zh)	2004-11-10
CA2691739A1 (fr)	2001-11-15
HUP0302190A2 (hu)	2003-10-28
TWI225787B (en)	2005-01-01
EA004871B1 (ru)	2004-08-26
BR0110620A (pt)	2003-04-01

Publication	Publication Date	Title
NO950297D0 (no)	1995-01-26	Prolinamidderivater
EP1246622A4 (fr)	2004-06-16	Nouvelles formes posologiques de benzimidazole substitue
MA26926A1 (fr)	2004-12-20	Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.
AR028706A1 (es)	2003-05-21	Tiazina oxazolidinona
JO2239B1 (en)	2004-10-07	Method for preparing benzothophen derivatives
MY125099A (en)	2006-07-31	Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
MY135954A (en)	2008-07-31	Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
EG24223A (en)	2008-11-10	Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof
FI933719A0 (fi)	1993-08-24	4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
BR9812982A (pt)	2000-08-08	Agente anti-reumático
MY141869A (en)	2010-07-16	Mouth rinse compositions
DE60127535D1 (de)	2007-05-10	Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
DK0913151T3 (da)	2002-10-14	Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel
FI20001721L (fi)	2001-01-30	6-hydroksi-3-(4-(/2-(piperidin-1-yyli)etoksi)fenoksi)-2-(4-metoksifenyyli)bentso(b)tiofeenihydrokloridin uusin kiteinen muoto
EP1757291A3 (fr)	2009-07-15	Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
DK1174131T3 (da)	2007-02-05	Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
SE9904412D0 (sv)	1999-12-03	Comminuted form
NZ505994A (en)	2003-10-31	Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
DK0925785T3 (da)	2002-07-01	Stabiliseret farmaceutisk præparat indeholdende dopamin eller dobutamin
WO2002022567A8 (fr)	2002-06-20	Nouveaux thio-derives de sordarine comme agents antifongiques
TW200503680A (en)	2005-02-01	S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate form ii crystalline salt
NO20010244L (no)	2001-01-15	Medikamenter inneholdende polyhydroksyalkylpyrazinderivater, deres fremstilling samt medikamenter inneholdende derivatene
TH61673A (th)	2004-04-26	สูตรผสมที่เพิ่มความคงตัวของ 6-ไฮดรอกซี-3-(4-[2-(พิเพอริดิน-1-อิล)เอทอกซี]ฟีนอกซี)-2-(4-เมทอกซีเฟนิล)เบนโซ[b]ไทโอฟีนและเกลือของสารดังกล่าว
ES2150392B1 (es)	2001-07-01	"composiciones parenterales a base de calcitonina".